Abstract
Transcatheter closure of patent foramen ovale (PFO) for prevention of recurrent cryptogenic cerebrovascular events (CVE) has not been officially approved in Japan. However, previous studies suggested that >10000 patients/year are suffered from a cryptogenic stroke due to PFO in Japan. Additionally,
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
